J&J cuts jobs and invests in core brands
This article was originally published in The Rose Sheet
Executive Summary
Johnson & Johnson will eliminate 6% to 7% of its global workforce in response to external pressures on the health care industry, the company announced Nov. 3. Cuts will come across all three of the company's core businesses: consumer products, pharmaceuticals and medical devices. Eliminations will take place globally, but mostly outside the U.S., and will reduce "layers of management," CEO William Weldon said during a same-day conference call. The plan will yield pre-tax cost savings of $1.4 bil. to $1.7 bil. in 2011, with $800 mil. to $900 mil. expected to be achieved in 2010. J&J plans to invest the savings in key innovation opportunities and core businesses, including "iconic brands," such as mouthwash Listerine and skin care lines Aveeno and Neutrogena, Weldon said
You may also be interested in...
Neutrogena introduces online holiday shopping destination
Johnson & Johnson brand launches Holiday.Neutrogena.com, an "easy-to-use beauty gifting resource offering a range of top-selling and favorite cleansing, acne, anti-aging and body care products," J&J announces. Purchases from the collection can be made for a limited time through January 2010. Products include Complete Acne Therapy System for $19.99, Neutrogena Wave Power Cleanser for $12.99 and Oil-Free Acne Wash Pink Grapefruit Foaming Scrub for $7.99. J&J's recent job cuts will result in investments in core brands, such as Neutrogena (1"The Rose Sheet" Nov. 9, 2009)
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.